NEWS 2/2

Muvon

CEO Deana Mohr presented MUVON in interview for BioInnovation Spotlight

Our CEO Deana Mohr had the great opportunity to present MUVONs vision and innovative regenerative cell therapy in an interview for...

Muvon

Translation and automation hurdles for cell therapies

Informative article published in BioInsights, written by our CSO Jenny Prange and our innovation manager Beatrix Rauch Schmid. This...

Muvon

MUVON wins second place at IFAS Innovation Challenge 2021

MUVON Therapeutics was selected as one of twelve finalists for 2021's IFAS Innovation Challenge and placed second in the final pitching...

Muvon

Deana Mohr wins spot in Venture Leaders Medtech 2021

MUVON Therapeutics CEO Deana Mohr was selected as one of ten Venture Leaders in Medtech to represent the Swiss National Startup Team in...

Muvon

MUVON featured by Startupticker

MUVON was featured in an article by Startupticker describing our regenerative approach for the treatment of incontinence and the progress...

Muvon

MUVON Therapeutics selected as finalist for the 2021 >>venture>> Startup Competition

MUVON is excited to have been selected as one of the top 10 startups in the Health and Nutrition vertical of the 2021 >>venture>> startup...

Muvon

MUVON Therapeutics selected for Tech4Eva accelerator program

MUVON Therapeutics is proud to have been selected as one of 30 start-ups and projects from around the world to join Switzerlands first...

Muvon

MUVON is being accelerated by Wyss Zurich

MUVON Therapeutics is proud to announce the acceptance as a Wyss Zurich Project starting April 2021. The Wyss Zurich is a joint...

Muvon

The Beginning of the MUVON Story

In October 2020 MUVON Therapeutics Ltd. was founded. The technology behind MUVON was developed over the past decade at the University of...